Iambic Therapeutics, Inc. has reported significant stock transactions conducted by its Chairperson, William H. Rastetter. The transactions, which occurred on October 16, 2026, are noteworthy as they reflect a strategic move within the company, potentially indicating confidence in its future prospects.

Rastetter acquired a total of 200,920 shares of common stock through various transactions. This includes the acquisition of 192,579 shares and an additional 8,341 shares, emphasizing a substantial investment in the company. The filing highlights that these shares were obtained at a price of zero, as they were part of a conversion from preferred stock to common stock.

Background

Iambic Therapeutics, Inc. is classified under the Standard Industrial Classification (SIC) code 2836, which pertains to Biological Products, (No Diagnostic Substances). The company trades on the Nasdaq under the ticker symbol IAM. The firm is based in San Diego, California, and focuses on developing innovative biological products.

What the Filing Says

The recent filing indicates that Rastetter's transactions involved the conversion of several series of preferred stock into common stock. Specifically, Rastetter converted:

76801 shares of Series B Convertible Preferred Stock, 64001 shares of Series B-2 Convertible Preferred Stock, 36805 shares of Series B-3 Convertible Preferred Stock, 14972 shares of Series B-4 Convertible Preferred Stock, and 8341 shares of Convertible Promissory Notes.

Following these transactions, Rastetter now holds a total of 200,920 shares of common stock in Iambic Therapeutics.

Impact

This update may have implications for various stakeholders, including investors, employees, and competitors in the biological products sector. The significant stock purchases by Rastetter may signal to investors a strong belief in the company's strategic direction and future growth. Other companies in the biological products industry may observe these developments closely as they assess their own market strategies.

What's Next

The filing does not say what happens next.